Press Releases

BioIVT Highlights Advances in Assessing a Drug Candidate’s Risk of Producing Liver Damage at the Society of Toxicology Annual Meeting and ToxExpo

By Lauren Vagnone | March 12, 2018

BioIVT will present a workshop and two poster sessions, and also exhibit at this year’s conference

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be making several scientific contributions to the Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo. This event will be held from Mar. 11-15 at the Henry B. González Convention Center in San Antonio, Texas.
Read more

BioIVT Launches New Website, Highlighting Expanded Biospecimen Product and Service Portfolios for Drug Development Researchers

By Lauren Vagnone | March 4, 2018

Website also sports new scientific resources, streamlined navigation, and enhanced search functionality.

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced the launch of its comprehensive, new, user-friendly website at www.bioivt.com. This launch coincides with the introduction of BioIVT’s new logo and marks the culmination of its new brand rollout.

“BioIVT has greatly expanded its product and service portfolios during the past few months with its acquisitions of Asterand Bioscience™ and Qualyst Transporter Solutions in August 2017 and September, 2017, respectively,” said Courtney Noah, PhD, BioIVT Vice President of Marketing. “We developed this new company website to share our vision, display our entire range of biospecimen and value-added service offerings in one place, and demonstrate new ways in which we can partner with drug researchers to elevate science.” …
Read more

BioIVT to Host Webinar on Early Phase Drug Development and the FDA’s Predictive Toxicology Roadmap

By Lauren Vagnone | January 30, 2018

Former FDA official will discuss toxicity and safety evaluation trends, and best practices for predicting toxicity risk.

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it is hosting a webinar entitled “Early Phase Drug Development and the FDA’s Predictive Toxicology Roadmap” at 11 a.m. ET on Feb. 1. “Significant drug development research focus is placed on reducing Phase 2 attrition and optimizing Phase 3 clinical studies, but improving predictive toxicology results at the pre-clinical stage is equally important,” said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. “Our ADME-Tox models can…
Read more

BioIVT Launches Scientific Advisory Board, Expands Drug Development Expertise

By Lauren Vagnone | January 11, 2018

New SAB members include a Nobel Laureate, modeling and simulation guru, pediatric oncologist, and bioanalytical operations and infectious disease experts

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced the launch of its BioIVT Scientific Advisory Board (SAB). BioIVT’s eminent and world-renowned SAB members will provide the company with scientific and business insights and help it to identify future growth areas.

“During the past year, with our acquisition of Asterand Bioscience and Qualyst Transporter Solutions, BioIVT has evolved from a global biological products provider into a true drug discovery research partner. We now offer a comprehensive range of cell processing, target and biomarker validation, ADME-toxicology, and phenotypic and clinical assay development services, in addition to producing control and disease-state matrices,” said BioIVT’s Chief Scientific Officer Dr. Chris Hansis…
Read more 

BioIVT Introduces New Products and Services to Improve Safety, Efficacy and Toxicity Testing for Skin Care Products, Cosmetics and Topical Medications

By Lauren Vagnone | November 27, 2017

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is launching a new line of products and services to improve safety, efficacy and toxicity testing for skin care products, cosmetics and topical medications.

“As the demand for personal skin care products increases – whether they are applied for anti-aging, hydration, wound healing or UV protection purposes – so does the need for better safety, efficacy and toxicity testing systems. The same holds true for new cosmetics and topical medications,” said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. “At BioIVT, we are endeavoring to provide researchers in those fields with biological systems that allow them to more clearly understand the disposition of topical applications and their effects on normal and disease-affected skin.”…
Read more

BioIVT to Host Webinar on the Impact of New FDA Draft Guidance on In Vitro Drug-Drug Interaction (DDI) Studies

By Lauren Vagnone | November 27, 2017

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it will host a one-hour webinar entitled: “The New FDA Draft Guidance on In Vitro DDI Studies: How Will It Impact You?” at 11 a.m. ET on Nov. 29. Toxicology experts Dr. Andrew Parkinson, CEO of XPD Consulting, and Dr. Ron Laethem, lead, in vitro services at Qualyst Transporter Solutions, a BioIVT company, will discuss how the guidance has changed and how it will impact drug development strategies…
Read more

BioIVT to Present Advances in Immunohistochemistry at AAPS Annual Meeting

By Lauren Vagnone | November 7, 2017

BioIVT will also showcase its expanded research services resulting from its Qualyst Transporter Solutions and Asterand Bioscience™ acquisitions earlier this year

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be presenting and exhibiting at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. This conference will be held from Nov. 12-15 at the San Diego Convention Center in San Diego, CA.

“BioIVT is proud to support AAPS, share our knowledge and experience, and help to support the next generation of pharmaceutical scientists. High content immunohistochemistry (IHC) is an exciting and rapidly-evolving field, and at BioIVT we are expanding our expertise and services to ensure that we continue to meet researchers’ growing needs,” said Dr. Amanda Woodrooffe, BioIVT vice president and general manager, UK…
Read more

BioIVT Expands Its Support for Precision Medicine Researchers

By Lauren Vagnone | October 24, 2017

BioIVT is sponsoring the Powering Precision Health Summit 2017 and showcasing its precision medicine product and services portfolio

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is sponsoring the Powering Precision Health Summit (PPHS) 2017. This conference will bring together leaders in biomarker research and translational medicine to present the latest advances in their disciplines. It will be held from Oct. 24-25 at the Charles Hotel in Cambridge, MA…
Read more

BioIVT Expands its Support of the Annual North American ISSX Meeting; Highlights Advances in Drug Metabolism and Toxicology Research

By Lauren Vagnone | September 21, 2017

BioIVT is sponsoring two symposia, giving several presentations, and exhibiting at this year’s conference

Westbury, NY –  BioIVT, a leading provider of biospecimens and related services, today announced that it is increasing its support of the annual North American International Society for the Study of Xenobiotics (ISSX) Meeting. BioIVT will be sponsoring two symposia, giving several presentations, and exhibiting at this year’s conference. This event will be held from Sept. 24-28 at the Rhode Island Convention Center in Providence, RI…
Read more

BioIVT Acquires Qualyst Transporter Solutions, Enables Researchers to Predict New Drug Candidates’ Impact on the Liver

By Lauren Vagnone | September 7, 2017

Acquisition will expand BioIVT’s ADME-Toxicology product line

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it has acquired Qualyst Transporter Solutions, LLC. Qualyst provides in vitro hepatic models and services that predict the effect of drugs and other compounds on the human liver in the pharmaceutical, chemical, consumer products, and cosmetics industries.

Qualyst uses a unique cell-based testing approach to predict compound clearance, drug-drug interactions, and toxicity in the human liver. In fact, it established the industry standard for hepatocytes; its Transporter Certified™ hepatocyte program ensures that cells, under defined culture conditions, maintain physiologic transporter uptake and efflux levels which are critical for normal function…
Read more